Angels for Change announced a major milestone in Project PROTECT, its national initiative focused on building ready-to-activate domestic manufacturing capacity for essential medicines vulnerable to shortages. Through the partnership, Leiters Health, a U.S.-based 503B outsourcing facility in Englewood, Colorado, has completed development of Magnesium Sulfate Injection and advanced the medicine into PROTECT's readiness phase. The partnership establishes domestic manufacturing capacity that can be activated when supply disruptions threaten access to this critical medication.
The newest Change Maker Chronicle is here! Drug shortages are still impacting patients every day, but together we are pushing forward. See how we’re raising awareness, fostering advocacy, and building resilent drug supply chains to end drug shortages NOW.
Drug shortages continue to put patients at risk.
As highlighted by The National Desk’s Spotlight on America, children with cancer and their families continue to face uncertainty when critical medicines like ifosfamide are in short supply.
For Abby Bray, this was personal. Patient One was Abby. Her experience navigating drug shortages during cancer treatment became the catalyst for Laura Bray’s advocacy and the founding of Angels for Change.
We remain committed to advancing solutions that strengthen the pharmaceutical supply chain and ensure every patient has access to the medicines they need.
Women across the country are struggling to access estrogen patches, with some traveling long distances, rationing medication, or searching for alternatives to maintain access to their treatment.
The New York Post recently examined the shortage and the challenges patients are facing. Laura Bray, Founder of Angels for Change, spoke with the publication about why the shortage was predictable following the FDA’s removal of the black box warning for estrogen-based hormone replacement therapy.
Announcing: A new milestone to strengthen U.S. readiness for critical medicines.
Today, Angels for Change and Medivant Healthcare announced the completion of a key Project PROTECT milestone, establishing ready-to-activate U.S. manufacturing capacity for 10% Calcium Chloride Injection, an essential medicine used in emergency and critical care.
Through the partnership, Medivant has completed development of Calcium Chloride Injection and advanced the medicine into Project PROTECT’s readiness phase, creating domestic manufacturing capacity that can be activated when supply disruptions threaten patient access.
“Project PROTECT is about staying ahead of shortages before they reach patients,” said Laura Bray, Chief Change Maker at Angels for Change. “By partnering with Medivant Healthcare to prepare domestic capacity for Calcium Chloride Injection, we are demonstrating what proactive shortage preparedness can look like and building the ability to respond before a supply disruption becomes a patient crisis.”
Since launching in 2022, Project PROTECT has strengthened U.S. readiness for 14 essential medicines, seven of which have subsequently experienced shortages, with more than 850,000 patient treatments accessed during shortages.
“After listening to families and many other organizations at the center of this community, including the Children’s Oncology Group and Angels for Change, we embarked on an aggressive development path to bring a new recombinant erwinia asparaginase option to market, one that will be manufactured under the highest quality standards and provide a reliable supply to meet the needs of our patients.”
SHARE YOUR “WHY”
Every conversation, partnership, and shared story brings us closer to a future without drug shortages. At Angels for Change, we’re proud to march forth for patients everywhere.
